Company profile
Pulmonx Corporation
NASDAQ: LUNG · Healthcare · Medical - Devices
#358 of 1,422 Healthcare companies by revenue53rd-percentile growth
EA Score
57CFH 48DQ 67GM 66SS 56
v0.1 · 65/100 weight · provisional
↑ filing timeliness, growth stability · ↓ listing tenure, return on equity
Methodology →Revenue TTM
$88.5M
Rev growth YoY (TTM)
+1.2%
Net income (FY)
-$54.0M
Employees
296
as of 2026-08-19
Market cap
$95.5M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$90.5M$90.5M2025
Net income-$54.0M-$54.0M2025
Operating income-$53.7M-$53.7M2025
Total assets$129.3M$129.3M2025
Liabilities$75.2M$75.2M2025
Equity$54.1M$54.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Pulmonx Corporation’s revenue?
Pulmonx Corporation booked $90.5M in FY2025 revenue, growing 8.0% year over year — about the middle of the pack among Healthcare companies we track, at a -59.7% net margin.
Peers · Healthcare
Butterfly Network, Inc.62CBioLife Solutions, Inc.74BSIGA Technologies, Inc.73BVaso Corporation68BCeriBell, Inc.49DBiodesix, Inc.57CNeighbors
San Mateo →Key facts
CEOGlendon E. French
SectorHealthcare
IndustryMedical - Devices
HeadquartersRedwood City, CA
ExchangeNASDAQ: LUNG
Employees296
IPO date2020-10-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.